PET Scans for Neuroendocrine Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to improve how doctors evaluate PET scans for individuals with neuroendocrine tumors, rare cancers that can occur in various parts of the body. Researchers seek to develop new criteria or guidelines to better predict whether a person's cancer is improving, worsening, or remaining stable. They will compare these new guidelines with the current ones to determine which is more effective. This study suits individuals diagnosed with somatostatin-receptor positive neuroendocrine tumors that cannot be surgically removed and are considering treatment with Peptide Receptor Radionuclide Therapy (PRRT). As a Phase 2 trial, this research focuses on measuring the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to significant advancements in cancer care.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What prior data suggests that these new criteria for evaluating PET scans are safe for use in patients with neuroendocrine tumors?
Research has shown that PET scans are generally safe for people with neuroendocrine tumors. In past studies, such as one using 68Ga-DOTATATE PET/CT scans, no harmful side effects requiring treatment were reported. Patients did not experience negative reactions from the scans. These studies suggest that PET scans are well-tolerated and can reliably diagnose and manage neuroendocrine tumors.12345
Why are researchers excited about this trial?
Researchers are excited about this trial because it aims to refine how PET scans are used for people with neuroendocrine tumors. Unlike traditional imaging techniques, PET scans can provide more detailed information about tumor activity and metabolism. This study could lead to better criteria for interpreting these scans, potentially improving diagnosis and monitoring of treatment responses. By enhancing our understanding of PET scan results, doctors could tailor treatments more effectively, leading to better outcomes for patients with neuroendocrine tumors.
What evidence suggests that these new criteria for evaluating PET scans are effective for neuroendocrine cancer?
Studies have shown that PET scans effectively check for neuroendocrine tumors. These scans accurately detect tumors and often outperform regular CT scans in spotting cancer. Research indicates that PET scans can help predict patient survival by identifying aggressive tumors. One study found that PET scans can surpass traditional methods in predicting tumor behavior. Overall, evidence supports using PET scans as a reliable tool for evaluating neuroendocrine cancer. Participants in this trial will undergo PET/CT or MRI scans as part of this non-interventional observational study.46789
Who Is on the Research Team?
Lisa Bodei, MD, PhD
Principal Investigator
Memorial Sloan Kettering Cancer Center
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Imaging and Evaluation
Participants undergo PET/CT or MRI scans to establish and validate new criteria for evaluating neuroendocrine tumors
Follow-up
Participants are monitored for safety and effectiveness after imaging and evaluation
What Are the Treatments Tested in This Trial?
Interventions
- PET Scan
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
This is a non-interventional observational study of imaging.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Memorial Sloan Kettering Cancer Center
Lead Sponsor
NeuroEndocrine Tumor Research Foundation (NETRF)
Collaborator
Citations
ESR Essentials: role of PET/CT in neuroendocrine tumors ...
In this article, we evaluate the importance and role of hybrid imaging with Positron emission tomography/ computer tomography (PET/CT) in patients with NEN.
Molecular Imaging for Response Assessment of ...
SST PET/CT has been demonstrated to show a very high accuracy in SST-expressing tumor lesions, frequently outperforming diagnostic-CT both at primary and ...
Prognostic Value of 18F-FDG PET/CT in a Large Cohort of ...
F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res. 2010;16:978–985 ...
Structured reporting of neuroendocrine tumors in PET/CT ...
Our study is the first to investigate whether a structured narrative report (SR) for staging neuroendocrine tumor (NET) patients with ...
The role of combined FDG and SST PET/CT in ...
Evidence suggests FDG PET/CT can outperform WHO grading in predicting outcomes by identifying aggressive, undifferentiated tumor clones that ...
Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis ...
Ga-DOTATATE PET/CT was equivalent or superior to 111In-pentetreotide imaging in all 78 patients. No adverse events requiring treatment were observed. 68Ga- ...
The Impact of 68 Ga-DOTATATE PET/CT Imaging on ...
Conclusion: 68Ga-DOTATATE PET/CT scanning is safe and influences management in a large proportion of patients. Prognosis was dependent on tumor ...
Positron Emission Tomography (PET) - Medical Clinical ...
Head-to-head comparison of 64Cu-DOTATATE and 68Ga-DOTATOC PET/CT: A prospective study of 59 patients with neuroendocrine tumors. J Nucl Med. 2017;58(3):451 ...
Neuroendocrine Tumor Diagnosis and Management
Gallium-68 DOTATATE PET/CT has good diagnostic accuracy to detect distant metastases and can have significant impact on patient management (Fig. 3). The liver ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.